Erratum: Up-regulation of pVHL along with down-regulation of HIF-1a by NDRG2 expression attenuates proliferation and invasion in renal cancer cells (PLoS ONE (2013) 8:12 (e84127) DOI:10.1371/journal.pone.0084127);Up-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Gao, Lei ^a,b,c   Wu, Guo Jun ^d   Liu, Bei ^b   Shen, Ming Zhi ^e   Pan, Tie Jun ^c   Yu, Chui Gong ^f   Wang, Qin Hao ^a   Ru, Yi ^a   Liu, Xi Ping ^a   Niu, Tian Shui ^a   Wang, Guo Dong ^b   Wei, Ming ^d   Li, Rui Xiao ^b   Yao, Libo ^b   Wang, He ^b   Li, Xia ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e PLA GENERAL HOSPITAL   (China)

^f GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MOUSE; N MYC DOWNSTREAM REGULATED GENE 2; NONHUMAN; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

EID: 84893492871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095904     Document Type: Erratum

References (42)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62: 283-298. doi:10.3322/caac.21153. PubMed: 22987332.
2. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373: 1119-1132. doi:10.1016/S0140-6736(09)60229-4. PubMed: 19269025.
3. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004. doi:10.1200/JCO.2004.05.061. PubMed: 15611513. (Pubitemid 46646218)
4. Kaelin WG (2007) Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173. doi:10.1146/annurev.pathol.2.010506.092049. PubMed: 18039096.
5. Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A et al. (2010) VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 34: 806-815. doi:10.1097/PAS.0b013e3181ddf54d. PubMed: 20431476.
6. Kapitsinou PP, Haase VH (2008) The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15: 650-659. doi:10.1038/sj.cdd.4402313. PubMed: 18219317. (Pubitemid 351405068)
7. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446. doi:10.1126/science.7660130. PubMed: 7660130.
8. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94: 2156-2161. doi:10.1073/pnas.94.6.2156. PubMed: 9122164. (Pubitemid 27136844)
9. Kaelin WG Jr. (2005) The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 338: 627-638. doi:10.1016/j.bbrc.2005.08.165. PubMed: 16153592.
10. Ivan M, Kondo K, Yang H, Kim W, Valiando J et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468. doi:10.1126/science.1059817. PubMed: 11292862. (Pubitemid 32335941)
11. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185. doi:10.1016/j.cmet.2006. 02.002. PubMed: 16517405.
12. Li L, Kaelin WG Jr. (2011) New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25: 667-686. doi:10.1016/j.hoc.2011.04. 004. PubMed: 21763962.
13. Chen D, Li M, Luo J, Gu W (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278: 13595-13598. doi:10.1074/jbc.C200694200. PubMed: 12606552. (Pubitemid 36799889)
14. Wang YQ, Luk JM, Ikeda K, Man K, Chu AC et al. (2004) Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 317: 358-362. doi:10.1016/j.bbrc.2004.03.050. PubMed: 15063765. (Pubitemid 38452490)
15. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ et al. (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22: 395-405. doi:10.1016/j.molcel.2006.04.006. PubMed: 16678111.
16. Deng Y, Yao L, Chau L, Ng SS, Peng Y et al. (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106: 342-347. doi:10.1002/ijc.11228. PubMed: 12845671. (Pubitemid 36870394)
17. Hu XL, Liu XP, Lin SX, Deng YC, Liu N et al. (2004) NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol 10: 3518-3521. PubMed: 15526377. (Pubitemid 39549557)
18. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF et al. (2007) Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 7: 192. doi:10.1186/1471-2407-7-192. PubMed: 17935612.
19. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P et al. (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65: 7121-7126. doi:10.1158/0008-5472.CAN-05-0043. PubMed: 16103061. (Pubitemid 41161241)
20. Gao L, Wu GJ, Liu XW, Zhang R, Yu L et al. (2011) Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene. Cancer Lett 310: 94-100. doi:10.1016/j.canlet.2011.06.015. PubMed: 21741166.
21. Yu C, Wu G, Dang N, Zhang W, Zhang R et al. (2011) Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma. Cancer Biol Ther 12: 304-313. doi:10.4161/cbt.12.4.16382. PubMed: 21623166.
22. Ma J, Liu W, Yan X, Wang Q, Zhao Q et al. (2012) Inhibition of endothelial cell proliferation and tumor angiogenesis by up-regulating NDRG2 expression in breast cancer cells. PLOS ONE 7: e32368. doi:10.1371/journal.pone. 0032368. PubMed: 22393400.
23. Ma J, Jin H, Wang H, Yuan J, Bao T et al. (2008) Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 31: 1316-1320. doi:10.1248/bpb.31.1316. PubMed: 18591767. (Pubitemid 351930639)
24. Ma JJ, Liao CG, Jiang X, Zhao HD, Yao LB et al. (2010) NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498. J Exp Clin Cancer Res 29: 103. doi:10.1186/1756-9966-29-103. PubMed: 20673333.
25. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ et al. (2008) Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 294: R393-R401. PubMed: 18056981.
26. Caceres W, Cruz-Chacon A (2011) Renal cell carcinoma: molecularly targeted therapy. P R Health Sci J 30: 73-77
27. Struckmann K, Mertz K, Steu S, Storz M, Staller P et al. (2008) pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 214: 464-471. PubMed: 18189328. (Pubitemid 351340566)
28. Haase VH (2012) Renal cancer: oxygen meets metabolism. Exp Cell Res 318: 1057-1067. doi:10.1016/j.yexcr.2012.02.026. PubMed: 22406000.
29. Baumunk D, Reichelt U, Hildebrandt J, Krause H, Ebbing J et al. (2013) Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC). World J Urol, 31: 1191-6. PubMed: 22544372.
30. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. doi:10.1038/nm0603-669. PubMed: 12778165. (Pubitemid 36749215)
31. Xu L, Zhu Y, Xu J, Wu K, Li J et al. (2012) Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling. Cancer Sci 103: 1253-1258. doi:10.1111/j.1349-7006.2012.02291.x. PubMed: 22463491.
32. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-660. doi:10.1038/nm0603-653. PubMed: 12778163.
33. Shoji K, Murayama T, Mimura I, Wada T, Kume H et al. (2013) Sperm-Associated Antigen 4, a Novel Hypoxia-Inducible Factor 1 Target, Regulates Cytokinesis, and Its Expression Correlates with the Prognosis of Renal Cell Carcinoma. Am J Pathol, 182: 2191-203. PubMed: 23602831.
34. Kim YJ, Yoon SY, Kim JT, Song EY, Lee HG et al. (2009) NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 30: 598-605. doi:10.1093/carcin/bgp047. PubMed: 19237607.
35. Liang ZL, Kang K, Yoon S, Huang SM, Lim JS et al. (2012) NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Ann Surg Oncol 19: 2763-2772. doi:10.1245/s10434-011-2204-3. PubMed: 22246425.
36. Hegele A, Varga Z, von Knobloch R, Heidenreich A, Kropf J et al. (2002) TGF-beta1 in patients with renal cell carcinoma. Urol Res 30: 126-129. doi:10.1007/s00240-002-0245-6. PubMed: 12086018. (Pubitemid 36062411)
37. Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A et al. (2004) Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32: 317-322. doi:10.1007/s00240- 003-0360-z. PubMed: 15365652. (Pubitemid 39517954)
38. Ananth S, Knebelmann B, Grüning W, Dhanabal M, Walz G et al. (1999) Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59: 2210-2216. PubMed: 10232610. (Pubitemid 29217687)
39. Sjölund J, Boström AK, Lindgren D, Manna S, Moustakas A et al. (2011) The notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLOS ONE 6: e23057. doi:10.1371/journal.pone.0023057. PubMed: 21826227.
40. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68: 4210-4220. doi:10.1158/0008-5472.CAN-07-5040. PubMed: 18519680.
41. Qi H, Ohh M (2003) The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res 63: 7076-7080. PubMed: 14612498. (Pubitemid 37413442)
42. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI et al. (2009) Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 30: 927-936. doi:10.1093/carcin/ bgp072. PubMed: 19336468.